West Pharmaceutical Services Inc. (WST) Sets New 1-Year High at $81.80
West Pharmaceutical Services Inc. (NYSE:WST)’s share price reached a new 52-week high during mid-day trading on Thursday . The company traded as high as $81.80 and last traded at $81.80, with a volume of 97,633 shares. The stock had previously closed at $80.96.
A number of equities analysts have recently issued reports on WST shares. Jefferies Group reiterated a “hold” rating and issued a $67.00 price objective on shares of West Pharmaceutical Services in a report on Thursday, June 9th. Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $81.00 price objective for the company in a report on Wednesday, April 20th. Finally, Janney Montgomery Scott reiterated a “buy” rating and issued a $90.00 price objective (up from $69.00) on shares of West Pharmaceutical Services in a report on Friday, May 13th.
The firm’s 50 day moving average is $76.89 and its 200 day moving average is $69.29. The company has a market capitalization of $5.97 billion and a P/E ratio of 59.36.
West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 28th. The company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.03. The company had revenue of $388 million for the quarter, compared to analysts’ expectations of $384.58 million. During the same quarter last year, the firm posted $0.47 earnings per share. West Pharmaceutical Services’s revenue for the quarter was up 7.9% on a year-over-year basis. On average, equities analysts predict that West Pharmaceutical Services Inc. will post $2.22 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Wednesday, August 3rd. Investors of record on Wednesday, July 20th were given a dividend of $0.12 per share. The ex-dividend date of this dividend was Monday, July 18th. This represents a $0.48 annualized dividend and a yield of 0.59%.
In other West Pharmaceutical Services news, VP Daniel Malone sold 3,950 shares of the firm’s stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $74.95, for a total transaction of $296,052.50. Following the sale, the vice president now directly owns 30,666 shares of the company’s stock, valued at $2,298,416.70. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Thomas W. Hofmann sold 2,466 shares of the firm’s stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $73.57, for a total value of $181,423.62. Following the sale, the director now directly owns 34,506 shares in the company, valued at $2,538,606.42. The disclosure for this sale can be found here.
A number of large investors have bought and sold shares of the stock. First Trust Advisors LP boosted its stake in West Pharmaceutical Services by 104.5% in the fourth quarter. First Trust Advisors LP now owns 24,581 shares of the company’s stock worth $1,480,000 after buying an additional 12,560 shares in the last quarter. New York State Common Retirement Fund boosted its stake in West Pharmaceutical Services by 3.1% in the fourth quarter. New York State Common Retirement Fund now owns 69,200 shares of the company’s stock worth $4,167,000 after buying an additional 2,100 shares in the last quarter. State of Wisconsin Investment Board boosted its stake in West Pharmaceutical Services by 3.1% in the fourth quarter. State of Wisconsin Investment Board now owns 32,181 shares of the company’s stock worth $1,938,000 after buying an additional 962 shares in the last quarter. Vanguard Group Inc. boosted its stake in West Pharmaceutical Services by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 5,321,348 shares of the company’s stock worth $320,452,000 after buying an additional 46,295 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its stake in West Pharmaceutical Services by 17.9% in the fourth quarter. GSA Capital Partners LLP now owns 17,134 shares of the company’s stock worth $1,032,000 after buying an additional 2,601 shares in the last quarter.
West Pharmaceutical Services, Inc is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s products include stoppers and seals for vials, prefillable syringe components and systems, components for intravenous and blood collection systems, safety and administration systems, advanced injection systems, and contract design and manufacturing services.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.